FDA OKs studies with iBio/Fraunhofer plant-based vax

Plant-based product developer iBio, which announced just before Labor Day a deal with GE Healthcare and the Fraunhofer Center for Molecular Biotechnology to develop biopharma and vaccine manufacturing gear, announced Monday that the FDA has accepted its IND for a vaccine candidate. The product, based on the iBioLaunch technology platform, was made by Fraunhofer in its cGMP pilot facility in Newark, DE. It is anticipated that human clinical trials based upon this IND will start soon.

The iBioLaunch platform is a plant-based expression system for recombinant protein production. It requires no animal cells or genetically altered plants, which the company says slow the manufacturing process and raise its cost.

Fraunhofer invented the technology and has been developing it over the past eight years, says an announcement. The intellectual property is owned by iBio, which sponsors the platform's development for human healthcare purposes.

- here's the iBio release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.